Germany's G-BA Sets Out Financial-Based Criteria For Assessing Drugs Already On The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany's senior reimbursement body, the G-BA, has set out criteria – based on the financial success of products – to evaluate drugs already on the market.